6533b82cfe1ef96bd128f732

RESEARCH PRODUCT

“Unexpectedly high survival rate in very poor prognosis stage III B breast cancer patients receiving cisplatin-based primary chemotherapy. A multicenter Italian study”

subject

description

605 Background: Primary chemotherapy, as part of multimodality treatment, has become the standard of care for locally advanced breast cancer (LABC) to increase DFS, OS and conservative surgery. Stage III B is renowned as the worst of LABC, and despite appropriate therapy the majority of patients (pts) will experience distant metastases and death within 2–3 years. The optimal regimen and schedule of primary chemotherapy is uncertain. Aim of our study was to verify the efficacy of an original cisplatin-based regimen (PEV) in terms of response and survival. Methods: Between 1996 and 2001 72 consecutive III B pts were treated with primary chemotherapy: Cisplatin 50 mg/m2, Epirubicin 100 mg/m2, Vinorelbine 25 mg/m2 every 14 (44%) or 21 (66%) days for 4 (33%) or 6 (67%) cycles, followed by surgery, radiation, adjuvant CMF 1, 8 q28 x 6 cycles + - TAM. Median age was 50 y (29–70); 47% premenopausal; 75% T4 abc, 25% T4 d; 45% ER-; 69% PgR-; 46% Ki 67+; 40% G3; 87,5% clinical axillary nodes positive. Results: All p...